← Back to Home

Alcon acquires Neurotech for $550 million, adding intraocular cell therapy to its retinal portfolio

ENCELTO uses cells implanted in the eye to continuously release a protective protein, offering a treatment option for a rare retinal disease. With Alcon taking over, the challenge shifts from securing approval to enabling more patients to receive treatment.

By SURL BioNews

For patients whose retinal photoreceptors are gradually being lost, the value of treatment often lies in preserving remaining vision. Alcon announced on October 20 that it had acquired Neurotech Pharmaceuticals, adding the intraocular implantable cell therapy ENCELTO to its portfolio and further extending its existing retinal surgery business into biological therapies.

The transaction involved a payment of $550 million, with potential additional payments tied to commercial milestones and other conditions. Cravath, the law firm representing Neurotech, also confirmed these arrangements, but the announcement did not disclose the total amount or detailed thresholds for contingent payments. The Orange County Business Journal also reported that the Rhode Island-based biotech company had been acquired by Alcon.

ENCELTO, the centerpiece of the acquisition, received approval from the U.S. Food and Drug Administration (FDA) in March 2025 for adults with idiopathic macular telangiectasia type 2 (MacTel Type 2). This rare, progressive retinal degenerative disease damages the cells responsible for detecting light, causing irreversible loss of central vision. According to Alcon’s announcement, ENCELTO remains the only FDA-approved therapy for this indication and is available only in the United States.

ENCELTO encapsulates genetically modified allogeneic retinal pigment epithelial cells within a semipermeable membrane capsule that is surgically implanted in the eye. The cells continuously produce recombinant human ciliary neurotrophic factor (rhCNTF), delivering the protective protein to the retina with the aim of slowing photoreceptor loss. This design combines living cells, protein delivery and ophthalmic surgery, illustrating how it connects with Alcon’s existing business.

The key efficacy evidence is a slowing of degeneration. FDA review documents indicate that two randomized, sham surgery-controlled Phase 3 trials showed reductions of 54.8% and 30.6%, respectively, in the rate of expansion of retinal ellipsoid zone defect area in the treatment groups compared with the control groups over two years of follow-up. This imaging measure is used to assess photoreceptor preservation. However, functional outcomes were less consistent: in the second trial, between-group differences in retinal sensitivity, other visual function measures and vision-related quality of life measures did not reach statistical significance. The benefit of structural preservation therefore cannot be directly interpreted as restoration of vision.

Treatment also carries the burden of the implantation procedure. According to the prescribing information, associated risks include intraocular infection, retinal tears or detachment, vitreous hemorrhage, cataracts and delayed dark adaptation. Expanding use therefore requires commercial distribution channels, physicians experienced in vitreoretinal surgery and appropriate care.

Neurotech CEO Richard Small said Alcon’s commercial capabilities, scientific expertise and global scale are expected to expand patient access to treatment, an expectation also reflected in the Orange County Business Journal’s reporting. However, a global presence does not mean patients in every market already have access, and the acquisition announcement did not provide a specific launch timeline outside the United States. For this transaction, the next phase of success will depend on whether the treatment can be integrated into clinical services and how much visual function long-term use can preserve.

References

  1. Alcon
  2. Cravath, Swaine & Moore LLP
  3. Orange County Business Journal